RESMED INC

Australian Foundation Investment Company (AFI) boosts NTA, $9.8B portfolio, top holdings BHP, CBA, Macquarie—low 0.16% fee and long‑term equity focus.

Perennial ETF spots ResMed as a top health‑tech pick, noting its strong EBITDA growth, ESG focus, and growing reimbursement pathways that boost ROI for patients and investors.

ResMed’s recent 4 % share dip amid market volatility is offset by strong regulatory wins, robust safety data, and a 15 % efficacy boost from its new cloud‑based digital platform.

Investors learn how ResMed’s insider sales signal risk and strategy—tax, governance, and market moves—impacting shareholder value in the competitive sleep‑care sector.

Discover why ResMed Inc. offers a low‑risk growth option for Australian investors, balancing strong R&D, AI‑driven diagnostics, and regulatory challenges.

ResMed Q2 2024 results: 3.7% revenue growth, $198m operating income, and new AI‑powered CPAP launches. 2024 EPS guidance $8‑$8.20 shows strong strategic focus and telehealth expansion.

Insider sales and option exercises at ResMed reveal a balance of liquidity and confidence, while modest institutional holdings underline the company’s steady long‑term growth outlook.

ResMed’s stable share price, strong 11 % revenue growth and 27 % operating margin show a resilient medical‑device leader poised to capitalize on AI‑driven RPM and value‑based care, making it a standout for investors and payers alike.

ResMed’s institutional and executive holdings reveal strong mid‑cap stability, while regulatory and competitive shifts hint at future growth risks and opportunities.

Explore ResMed’s latest executive changes, ETF inclusion, and analyst focus—key insights into its governance, market stance, and future outlook.